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Abstract: Leuprolide is a gonadotropin-releasing hormone (GnRH) analog which has been shown to reduce symptoms in patients with 
irritable bowel syndrome (IBS) and chronic intestinal pseudo-obstruction (CIPO). The mechanism is not known, but one hypothesis 
is through down-modulation of luteinizing hormone (LH) secretion, a hormone whith antagonistic effect on gastrointestinal motility. 
However, presence of LH receptors in the gastrointestinal tract has never been described. The aim of this study was to find one possible 
way of action for leuprolide by examining the presence of the LH receptor, and if present, to see whether there was different expression 
in patients with or without dysmotility. Full-thickness biopsies from the bowel wall of patients with and without severe dysmotility were 
examined using immunohistochemistry staining. Biopsies showed expression of LH receptors on myenteric neurons and in glial cells, 
neutrophils, endothelial cells and mast cells. There was no difference in expression between patient groups.
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Introduction
Chronic  intestinal  pseudo-obstruction  (CIPO)  is  a 
disorder  affecting  gastrointestinal  motor  activity, 
producing symptoms and signs resembling those of 
mechanical obstruction.1–3 Enteric dysmotility (ED) 
encompasses patients with abnormal intestinal motor 
activity but no signs of obstruction.4 The etiologies of 
these two disorders are largely unknown.5   Leuprolide, 
a  gonadotropin-releasing  hormone  (GnRH)  analog, 
have  been  used  in  the  treatment  of  these    diseases 
as well as in patients with irritable bowel syndrome 
(IBS).6–8 The mechanism of action behind the reduc-
tion  of  symptoms  is  not  known.  One  hypothesis 
is  that  leuprolide  continuously  stimulates  the 
hypothalamic-  pituitary-gonadal  axis  and  thereby 
down-modulates the secretion of gonadotropines and 
gonadal products.9,10 These are in turn known to be 
neural antagonists of gastrointestinal motility11–13 and 
absence of these hormones could explain the improve-
ments seen. The effect on the gastrointestinal tract 
demands receptors for the substance, and receptors 
for progesterone and estrogen have been described in 
the gastrointestinal tract.14,15 The luteinizing hormone 
(LH) receptor was first described in gonadal tissues. 
During the last years it has also been described in 
several non-gonadal tissues and on cancer cells, but 
its expression in the gastrointestinal tract has never 
been  examined,16  although  LH  has  been  shown  to 
affect intestinal motility in rat.11
To  establish  a  possible  way  of  action  for  the 
reported effect of GnRH analogs and LH on gastroin-
testinal symptoms and motility, the aim of the present 
study was to examine the presence of LH receptors in 
the gastrointestinal tract, and if present, to compare 
the expression in patients with and without severe 
gastrointestinal dysmotility.
Material and Methods
This study was performed according to the Helsinki 
declaration and approved by the Ethics Committee 
of Lund University. All patients gave their informed 
consent before entering the study.
Subjects
The criterion for inclusion in the dysmotility group 
was the diagnosis of either CIPO or ED, together with 
a gastrointestinal specimen available for staining of 
LH receptors.
Consecutive  patients  subjected  to  laparoscopic 
full-thickness biopsy at the Departments of   Surgery 
or  Gastroenterology,  Skåne  University  Hospital, 
Malmö, between 1998 and 2009 because of severe 
gastrointestinal pain and dysmotility were identified 
and  included  in  a  retrospective  manner.  Thorough 
investigation  comprising  radiological  and/or  endo-
scopic  investigation  to  rule  out  organic  disease 
or  mechanical  obstruction  had  been  performed. 
Gastrointestinal  examination  was  completed  with 
esophageal  manometry,  gastric  emptying  scin-
tigraphy,  antroduodenojejunal  manometry  and/or 
colonic transit time when appropriate. Laparoscopy 
was  performed  for    diagnostic  purposes  to  exclude 
mechanical obstruction and to obtain a full-thickness 
biopsy. A previously described laparoscopy-assisted 
technique for taking full-thickness biopsies, prepar-
ing the biopsies and protocol for CIPO analysis was 
used.17 In addition, patients with severe dysmotility 
who underwent intestinal resection (including small 
or large bowel, or both) within the same time-frame 
were included, but were not considered for laparo-
scopic biopsy because full-thickness intestinal wall 
tissue was already available for analysis.
In order to set a CIPO diagnosis, patients had to 
fulfill 3 criteria: a medical history compatible with 
pseudo-obstruction,  documented  events  or  chronic 
signs  mimicking  mechanical  obstruction  (bowel 
dilatation  and/or  air/fluid  levels)  and  absence  of 
mechanical  obstruction  or  other  organic  cause  for 
these symptoms and findings.1–3 The criteria for ED 
were  documented  abnormal  contractile  activity, 
but  no  past  history  of  episodes,  or  current  signs, 
mimicking  mechanical  obstruction  and  absence 
of any medication that could lead to the observed 
motor abnormalities.2,4 These patients represent the 
majority of cases of suspected CIPO/ED in the most 
southern part of Sweden. Thirty-five patients fulfilled 
the inclusion criteria. Apart from the histochemical 
staining for CIPO analysis,17 representative sections 
were also available for staining of the LH receptor 
in  15  patients. The  median  age  of  the  15  patients 
(13 women) was 44 (range 18–96) years at the time 
of investigation. Ten patients were diagnosed with 
ED and 5 patients with CIPO. Seven of the patients 
had been treated by opioids, and 3 had some sort of 
nutritional  supplements.  Histopathological  analysis 
revealed  that  inflammatory  neuropathy  was  most LH receptor and gastrointestinal tract
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Table 1. Characteristics of the patients in the   dysmotility 
group.
patient characteristics number of  
patients
number of  




44 (range 18–96) 15 15





Ehler Danlos syndrome 1
Gynecological problems** 8 13
Endometriosis 2
Extra uterine pregnancy 2
Salpingo oophorectomized 2
Conization 1
In vitro fertilization 2
prior surgery** 10 15
Gynecological surgery 8
Abdominal surgery 8
multiple prior surgery 8
employment
Able to work full time 3 11
partly employed 1 11
Unable to work 4 11
Retired 2 11
Deceased 1 11
notes: *Excluding gynecological diseases; **some patients have more 
than one gynecological problem or prior surgery.
common  in  our  cohort,  either  as  an  independent 
disease  or  in  combination  with  myopathy  (9/15 
patients,  60%),  whereas  degenerative  neuropathy 
or  combined  myoneuropathy  occurred  in  40%  of 
the  patients  (6/15).  Twelve  small  bowel  specimen 
and 7 large bowel specimen were available for LH 
receptor staining with presence of ganglia, reflecting 
material from resections with both small and large 
bowel specimens present in 4 patients. For further 
patient characteristics, see Table 1.
As controls for LH-receptor +/- neurons in small 
bowel, sections from 6 cases of small bowel resec-
tion due to non-obliterating adenocarcinoma of the 
  jejunum and ileum, and 2 cases of colonic carcinoma 
were used, median age 69 (range 53–85) years. Three 
were  women.  Regarding  large  bowel,  the  control 
group was 8 cases (5 women) with bowel resection due 
to diverticulosis, median age 74 (range 46–87) years. 
The  samples  were  taken  from  areas  with  normal 
macro- and microscopic appearance 10 cm above the 
tumor in the small bowel and from diverticulum-free 
normal parts of the large bowel specimen. All con-
trols were found to have otherwise normal histology.
Full-thickness biopsy of the bowel
Full-thickness slices perpendicular to each other were 
cut from the specimen and embedded in paraffin for 
conventional,  transversal  sections.  The  remaining, 
larger part of the biopsy was embedded in toto for 
tangential sectioning. Serial sections from all blocks 
were stained according to a protocol for CIPO analy-
sis with both classical staining (haematoxylin & eosin, 
PAS,  PS-diastase,  Giemsa,  kresylviolet,  trichrome) 
and immunostaining.17 Apart from the histochemical 
staining for CIPO analysis, sections were also stained 
for the LH receptor. The polyclonal rabbit anti-LH 
receptor  antibody  (anti-LH/CG  receptor;  Sigma-
  Aldrich, Stockholm, Sweden) was applied to sections 
at 1:100 dilutions. As negative controls the antibodies 
were replaced by serum.
The  length  of  the  biopsy  was  measured  and 
the  number  of  the  LH  receptor  +/-  neurons  per 
mm  length  of  intestinal  muscle  in  the  transversal 
  sectioning was counted and expressed as percentage 
of neurons both in the dysmotility group and   controls. 
Using  protein  G  product  (PGP)  9.5  staining,  the 
  percentages of labeled cells from the initial countings 
were   verified. We found a strong correlation between 
the two methods, with a Spearman correlation coef-
ficient of 0.873, P = 0.000001 for the LH receptor in 
the small bowel. For the large bowel, the coefficient 
was 0.965 and P value was P = 0.000000001, for LH 
receptor content.
Statistical methods
Values  are  expressed  as  median  and  interquartile 
range (IQR) and range. Correlations were made by 
  Spearman’s correlation test. The Mann Whitney U-test 
was used to compare differences between groups, and 
P , 0.05 was considered statistical significant.
Results
The median length of counted biopsies for the small bowel 
was 16.00 (IQR 11.43–24.85, range 4.80–65.00) mm 
in the dysmotility group and 13.50 (IQR 10.25–16.75,   
range 10.00–35.00) mm in controls. In the large bowel, 
the median lenght was 30.00 (IQR 23.00–41.00, range Hammar et al
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9.00–60.40) mm in the dysmotility group and 17.5 
(IQR 11.00–19.00, range 10.00–23.00) mm in controls. 
The number of myenteric neurons per mm in the small 
bowel was 6.45 (IQR 5.25–7.38, range 2.40–21.00)   
in  the  dysmotility  group  compared  to  8.21  (IQR 
5.72–9.19,  range  5.34–15.23)  in  the  control  group 
(P = 0.43). Number of neurons per mm in the large 
bowel  was  5.50  (IQR  4.70–5.90,  range  4.30–7.70)   
in  the  dysmotility  group  compared  to  8.76  (IQR 
5.77–9.08,  range  5.00–10.71)  in  the  control  group 
(P = 0.04).
All specimens in both the dysmotility group and 
the control group had positive LH receptors. The LH 
receptor was positive in cytoplasm of approximately 
50% of myenteric neurons and in glial cells, neutro-
phils, endothelial cells and mast cells for both the 
dysmotility group and the controls (Fig. 1). A group 
of submucosal neurons were labeled for LH recep-
tors, but they were not counted as these neurons are 
not affected in patients suffering from dysmotility. 
All other cell types of the bowel wall were negative. 
No immunostaining was seen in the negative con-
trol sections. The percentage of labeled neurons in 
the dysmotility group was 42.50 (IQR 38.25–48.00, 
range 26.00–60.01)% in the small bowel and 50.00 
(IQR 23.00–51.00, range 12.00–59.00)% in the large 
bowel. In controls, the median value was 47.14 (IQR 
42.69–49.49, range 31.69–52.99)% and 43.40 (IQR 
42.14–46.48, range 32.53–47.44)% in the small and 
large bowel, respectively, which was not significant 
different  between  the  groups  (P  =  0.25  and  0.68, 
respectively).
Discussion
This is to the best of our knowledge the first time LH 
receptor expression in the human gastrointestinal tract 
has been described. The results suggest no difference 
in  the  receptor  expression  between  patients  with 
and without gastrointestinal dysmotility, or between 
genders.  The  dysmotility  group  had  significantly 
lower amount of enteric neurons per mm examined 
large bowel.
The  physiological  effect  of  LH  on  gastrointes-
tinal  tract  has  previously  only  been  rudimentary 
examined and has to be further investigated. So far, 
its antagonistic effect on gastrointestinal motility in 
rat has been described,11 which theoretically could be 
explained by the presence of LH receptors on myen-
teric neurons. Further, a protective and antioxidant 
effect by LH in rat gastric tissue has been described, 
but the importance of this is unclear.14
The presence of the receptor on endothelial cells, 
neutrophils, mast cells and glial cells suggests cir-
culatory, immunological and neuroprotective effects 
as well. Luteinizing hormone has been described to 
exert a wide range of effects on other tissues in dif-
ferent species. The LH receptor is a member of a sub-
family of G protein coupled receptors (GPCRs). It is 
well described for these receptors, that they are down-
regulated by continuous stimulation and up-regulated 
after intermittent stimulation.18 In a rat model, pres-
ence of LH receptors located in the vascular smooth 
muscle and endothelial cells of uterine blood vessels 
are hypothesized to be responsible for the reduced 
uterine blood flow after human chorionic gonadotropin 
(hCG)/LH stimulation.19   Exogenous administration of 
LH increased the number of degranulated mast cells 
in the ovarian complex of mice.20 This is interesting 
as mast cells have been discussed in the pathophysi-
ology of IBS and visceral hypersensitivity,21 and are 
expressed in an increased number in patients with 
severe constipation.22 Glial cells which are important 
Figure 1. Control myenteric ganglion with luteinizing hormone (LH) receptor 
positive neurons (thick, blue arrow) and one negative neuron (arrow). Glial 
cells within the ganglion and interstitial cells of Cajal (thin arrows) are 
immunoreactive (LH receptor immunohistochemistry; bar: 20 µm).LH receptor and gastrointestinal tract
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to support neuronal elements, have been shown to 
be  closely  related  to  degranulated  mast  cells,  and 
are  expessed  in  reduced  number  in  patients  with 
constipation.22,23 Fasting and refeeding affects the LH 
secretion in monkeys through cholecystokinin (CCK) 
stimulation.24 As mutations of the LH receptor have 
been  described  in  Leydig  cell  hypoplasia,25  muta-
tions could theoretically also affect gastrointestinal 
function.
The GnRH analog leuprolide has been shown to 
reduce  symptoms  in  disorders  such  as  functional 
bowel  diseases.7,8  Further,  leuprolide  has  been 
reported to restore motor function in the gastroin-
testinal tract in female ovariectomized rats and in a 
patient suffering from CIPO.6,26 The mechanism is 
unclear, but one hypothesis is that leuprolide by con-
tinuous  stimulation,  and  thereby  desensitization  of 
the  pituitary  GnRH  receptor,  down-modulates  the 
secretion of gonadotropines and gonadal products,9,10 
which are known neural antagonists of gastrointesti-
nal motility.11–13 Thus, continuous stimulation by leu-
prolide exerts antagonistic GnRH effects, leading to 
absence of LH secretion and stimulation.9,10 The pres-
ent finding of LH receptors on enteric neurons gives 
a morphological explanation to this hypothesis, and 
absence of LH stimulation on the neural receptors 
could explain the reduction of symptoms.11
At the same time as continuous stimulation of leu-
prolide acetate improves patients with gastrointestinal 
complaints,7,8  repeated  intermittent  treatment  with 
the analog buserelin in the setting of repeated in vitro 
fertilization (IVF) has been linked to the development 
of  CIPO  in  one  patient.17  Gonadotropin-  releasing 
hormone  and  its  receptor  have  been  found  on 
enteric neurons,17,27 why the effect evoked by GnRH 
  analogs may be direct on enteric neurons as well, in 
addition to an effect on the hypothalamic-pituitary-
gonadal axis.
The present study demonstrates the presence of 
LH receptors in the gastrointestinal tract, making 
it theoretically possible for this hormone to have 
a direct effect on this organ, and a possibility for 
GnRH  analogs  to  affect  the  gasrointestinal  tract. 
The role for regulation of expression and function 
of the LH receptor in the gastrointestinal tract has 
to be further investigated, as well as its possible 
involvement in the development of gastrointestinal 
disorders.
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